Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Clariscan |
| Active Ingredient: | Gadoteric acid 279.3mg/mL |
| Dosage Form: | Solution for injection |
| New Zealand Sponsor: | GE Healthcare Limited |
| Manufacturer: | GE Healthcare AS, Oslo, Norway |
| Product: | Ipol |
| Active Ingredients: | Polio virus type 1 40DAgU Polio virus type 2 8DAgU Polio virus type 3 32DAgU |
| Dosage Form: | Suspension for injection |
| New Zealand Sponsor: | Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics |
| Manufacturers: | Sanofi Pasteur SA, Marcy L’Etoile, France Sanofi Pasteur SA, Val-De-Reuil, France Sanofi Winthrop Industrie, Le Trait, France |
Dated this 1st day of December 2022.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).